JP2012512903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512903A5 JP2012512903A5 JP2011542487A JP2011542487A JP2012512903A5 JP 2012512903 A5 JP2012512903 A5 JP 2012512903A5 JP 2011542487 A JP2011542487 A JP 2011542487A JP 2011542487 A JP2011542487 A JP 2011542487A JP 2012512903 A5 JP2012512903 A5 JP 2012512903A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino acid
- group
- hydrogen
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 235000001014 amino acid Nutrition 0.000 claims 71
- 150000001413 amino acids Chemical class 0.000 claims 59
- 229910052739 hydrogen Inorganic materials 0.000 claims 49
- 239000001257 hydrogen Substances 0.000 claims 40
- 238000006467 substitution reaction Methods 0.000 claims 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 150000002431 hydrogen Chemical class 0.000 claims 25
- 108060003199 Glucagon Proteins 0.000 claims 21
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 19
- 229940002612 prodrug Drugs 0.000 claims 19
- 125000004429 atom Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 102000051325 Glucagon Human genes 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 15
- 229960004666 glucagon Drugs 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 14
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 12
- 238000012986 modification Methods 0.000 claims 12
- -1 aromatic amino acid Chemical class 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 8
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 8
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 7
- 238000003776 cleavage reaction Methods 0.000 claims 7
- 230000007017 scission Effects 0.000 claims 7
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims 6
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 150000002148 esters Chemical group 0.000 claims 5
- 235000013922 glutamic acid Nutrition 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 5
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 229960003104 ornithine Drugs 0.000 claims 4
- 230000004962 physiological condition Effects 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 150000007942 carboxylates Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- DNIFHMZTVZPEHP-VIFPVBQESA-N (2s)-2-[amino(naphthalen-1-yl)amino]propanoic acid Chemical compound C1=CC=C2C(N(N)[C@@H](C)C(O)=O)=CC=CC2=C1 DNIFHMZTVZPEHP-VIFPVBQESA-N 0.000 claims 1
- YJLGBPOTRWZBFH-JTQLQIEISA-N (2s)-2-hydrazinyl-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NN)C(O)=O)=CNC2=C1 YJLGBPOTRWZBFH-JTQLQIEISA-N 0.000 claims 1
- XJPHGGXFBWOHFL-QMMMGPOBSA-N (2s)-2-hydrazinyl-3-(4-hydroxyphenyl)propanoic acid Chemical compound NN[C@H](C(O)=O)CC1=CC=C(O)C=C1 XJPHGGXFBWOHFL-QMMMGPOBSA-N 0.000 claims 1
- AWPUZQSFPGSJPM-UHFFFAOYSA-N 2-(n-aminoanilino)acetic acid Chemical compound OC(=O)CN(N)C1=CC=CC=C1 AWPUZQSFPGSJPM-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 1
- 108010015792 glycyllysine Proteins 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 0 CC(C)(C(C)=O)N(*)C(C(C)(*)*)=O Chemical compound CC(C)(C(C)=O)N(*)C(C(C)(*)*)=O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13921008P | 2008-12-19 | 2008-12-19 | |
| US61/139,210 | 2008-12-19 | ||
| US14427109P | 2009-01-13 | 2009-01-13 | |
| US61/144,271 | 2009-01-13 | ||
| US18755609P | 2009-06-16 | 2009-06-16 | |
| US61/187,556 | 2009-06-16 | ||
| PCT/US2009/068745 WO2010071807A1 (en) | 2008-12-19 | 2009-12-18 | Amide based glucagon superfamily peptide prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095017A Division JP2015180649A (ja) | 2008-12-19 | 2015-05-07 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012512903A JP2012512903A (ja) | 2012-06-07 |
| JP2012512903A5 true JP2012512903A5 (enExample) | 2013-02-21 |
Family
ID=42269125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542487A Pending JP2012512903A (ja) | 2008-12-19 | 2009-12-18 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
| JP2015095017A Pending JP2015180649A (ja) | 2008-12-19 | 2015-05-07 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095017A Pending JP2015180649A (ja) | 2008-12-19 | 2015-05-07 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8969288B2 (enExample) |
| EP (2) | EP3075385A1 (enExample) |
| JP (2) | JP2012512903A (enExample) |
| KR (1) | KR20110110174A (enExample) |
| CN (1) | CN102325539A (enExample) |
| AR (1) | AR074811A1 (enExample) |
| AU (1) | AU2009327418A1 (enExample) |
| BR (1) | BRPI0922969A2 (enExample) |
| CA (1) | CA2747499A1 (enExample) |
| CL (1) | CL2011001498A1 (enExample) |
| IL (1) | IL213113A (enExample) |
| MX (1) | MX2011006524A (enExample) |
| PE (1) | PE20120332A1 (enExample) |
| RU (1) | RU2550696C2 (enExample) |
| SG (1) | SG172291A1 (enExample) |
| TW (1) | TWI489992B (enExample) |
| WO (1) | WO2010071807A1 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| EP2487184A1 (en) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| WO2009058734A1 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| JP2011511778A (ja) * | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| KR20110039230A (ko) * | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| BRPI0915282A2 (pt) * | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| MX2011006527A (es) * | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Agentes medicinales unidos a dipeptido. |
| SG172291A1 (en) * | 2008-12-19 | 2011-07-28 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
| CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| WO2010080606A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Insulin analogs |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| BRPI1014508A2 (pt) | 2009-06-16 | 2016-04-05 | Univ Indiana Res & Tech Corp | análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso" |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CN102834108A (zh) | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| JP5969469B2 (ja) | 2010-06-16 | 2016-08-17 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト |
| CN103119057B (zh) | 2010-06-24 | 2016-06-15 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| CN103179979A (zh) | 2010-06-24 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| WO2011162968A1 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| EA201390941A1 (ru) * | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| CN103402536A (zh) | 2010-12-22 | 2013-11-20 | 马克迪亚生物科技公司 | 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法 |
| CA2838503C (en) | 2011-06-10 | 2020-02-18 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| JP5914641B2 (ja) * | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
| TR201901402T4 (tr) | 2011-06-17 | 2019-02-21 | Hanmi Science Co Ltd | Oksintomodulin ve bir immünoglobulin fragmanı içeren bir konjugat ve onun kullanımı. |
| BR112013032717A2 (pt) * | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
| CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| EP2578599A1 (en) | 2011-10-07 | 2013-04-10 | LanthioPep B.V. | Cyclic analogs of GLP-1 and GLP-1 related peptides |
| ES2672880T3 (es) * | 2011-11-17 | 2018-06-18 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor de glucocorticoides |
| WO2013096386A1 (en) | 2011-12-20 | 2013-06-27 | Indiana University Research And Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
| US20150025002A1 (en) * | 2012-01-12 | 2015-01-22 | University Of Ulster | Peptides and peptide derivatives based on xenin |
| CN104185639B (zh) | 2012-03-01 | 2018-06-19 | 诺和诺德股份有限公司 | Glp-1前体药物 |
| DK2864350T3 (en) | 2012-06-21 | 2018-05-28 | Univ Indiana Res & Tech Corp | ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY |
| WO2013192129A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014052451A2 (en) | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Insulin analog dimers |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| EP3610856B1 (en) | 2012-11-06 | 2021-08-18 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| MX2015008077A (es) | 2012-12-21 | 2015-10-30 | Sanofi Sa | Derivados de exendina-4 como agonistas dobles de glp1/gip o trigonal de glp1-gip/glucagon. |
| JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| JP2016521253A (ja) * | 2013-03-15 | 2016-07-21 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | 持続性作用を有するプロドラッグ |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US20170037086A1 (en) * | 2014-04-09 | 2017-02-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with pth activity |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| CN107001441A (zh) | 2014-09-24 | 2017-08-01 | 印第安纳大学研究及科技有限公司 | 脂质化的基于酰胺的胰岛素前药 |
| WO2016065090A1 (en) * | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| JP6344348B2 (ja) | 2015-09-14 | 2018-06-20 | 株式会社デンソー | バッファ制御装置、通信ノード、及び中継装置 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US10793615B2 (en) | 2015-10-27 | 2020-10-06 | Merck Sharp & Dohme Corp. | Long-acting co-agonists of the glucagon and GLP-1 receptors |
| US20190175744A1 (en) * | 2016-03-18 | 2019-06-13 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
| CN109562144A (zh) * | 2016-06-09 | 2019-04-02 | 阿米德生物有限责任公司 | 胰高血糖素类似物及其使用方法 |
| KR20190057110A (ko) | 2016-09-28 | 2019-05-27 | 코바, 인크. | 치료적 mots-c 관련 펩타이드 |
| CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素（oxm）类似物及其应用 |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| EP3624828B1 (en) | 2017-05-18 | 2024-08-07 | Merck Sharp & Dohme LLC | Pharmaceutical formulation comprising incretin-insulin conjugates |
| PE20200678A1 (es) | 2017-06-16 | 2020-06-11 | Zealand Pharma As | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) |
| RU2721282C2 (ru) * | 2017-11-21 | 2020-05-18 | Илья Владимирович Духовлинов | Способ лечения рассеянного склероза (варианты) |
| JP2018090636A (ja) * | 2018-03-15 | 2018-06-14 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
| AU2020216135A1 (en) | 2019-01-28 | 2021-08-05 | Cohbar, Inc. | Therapeutic peptides |
| EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
| TW202315883A (zh) | 2020-07-22 | 2023-04-16 | 丹麥商諾佛 儂迪克股份有限公司 | 適用於口服的glp-1及gip受體共促效劑 |
| JP7484018B2 (ja) | 2020-11-06 | 2024-05-15 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１プロドラッグおよびその使用 |
| MX2023007498A (es) * | 2020-12-24 | 2023-07-05 | Hanmi Pharmaceutical Co Ltd | Terapia de combinacion del peptido insulinotropico y glp-2, para prevenir o tratar el sindrome del intestino corto. |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| IL316444A (en) * | 2022-04-18 | 2024-12-01 | Hanmi Pharmaceutical Co Ltd | Combination therapy involving GLP-2 together with an isulinotropic peptide, a TNF-α inhibitor, or both, for the prevention or treatment of colorectal disease |
| TW202346324A (zh) | 2022-05-10 | 2023-12-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| TW202421645A (zh) | 2022-11-25 | 2024-06-01 | 丹麥商諾佛 儂迪克股份有限公司 | 如ｇｌｐ—１之肽治療劑的口服投與 |
| WO2025147621A1 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Glucagon/glp-1/gip tri-agonists and their associated prodrugs |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740385A (en) * | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
| US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| DK119785D0 (da) | 1985-03-15 | 1985-03-15 | Nordisk Gentofte | Insulinpraeparat |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
| JPH04504416A (ja) | 1989-02-17 | 1992-08-06 | コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． | ペプチドの使用方法と合成方法 |
| EP0512042B1 (en) * | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| WO1997013500A2 (en) | 1995-10-12 | 1997-04-17 | Supergen, Inc. | LIPOSOME FORMULATIONS OF 5β STEROIDS |
| US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
| AU2263197A (en) | 1996-02-06 | 1997-08-28 | Eli Lilly And Company | Diabetes therapy |
| US6767887B1 (en) | 1996-06-05 | 2004-07-27 | Roche Diagnostics Gmbh | Exendin analogues, processes for their preparation and medicaments containing them |
| CA2265454A1 (en) * | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| WO1998024464A1 (en) | 1996-12-03 | 1998-06-11 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| EP1950223A3 (en) | 1998-03-09 | 2009-05-13 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| WO2000020592A1 (en) | 1998-10-07 | 2000-04-13 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| CN1495198A (zh) | 1998-12-07 | 2004-05-12 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 胰高血糖素样肽-1的类似物 |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| US6921748B1 (en) | 1999-03-29 | 2005-07-26 | Uutech Limited | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| AUPQ661800A0 (en) | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| KR20020097236A (ko) | 2000-04-27 | 2002-12-31 | 바이오네브라스카, 인코포레이티드 | 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| CA2410604A1 (en) | 2000-06-14 | 2001-12-20 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
| DE60137876D1 (de) | 2000-06-16 | 2009-04-16 | Lilly Co Eli | Analoge des Glucagon-ähnlichen Peptids-1 |
| CN1454214A (zh) | 2000-08-02 | 2003-11-05 | 赛莱技术公司 | 具有增高功效的修饰生物肽 |
| WO2002012201A1 (en) | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Method of synthesizing diketopiperazines |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| US7199217B2 (en) | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
| DE60228972D1 (de) | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| AU2002327430A1 (en) | 2001-08-08 | 2003-02-24 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| MXPA04001560A (es) | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| PL377687A1 (pl) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą |
| WO2003035099A1 (en) | 2001-10-19 | 2003-05-01 | Eli Lilly And Company | Biphasic mixtures of glp-1 and insulin |
| US20050014679A1 (en) | 2001-12-20 | 2005-01-20 | Beals John Michael | Insulin molecule having protracted time action |
| WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| WO2003058203A2 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| CA2477088A1 (en) | 2002-02-22 | 2003-10-02 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| EP1575490A4 (en) | 2002-06-04 | 2007-08-08 | Lilly Co Eli | MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) |
| EP1515746A2 (en) | 2002-06-11 | 2005-03-23 | Eisai Co. Ltd | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| EP1526864A4 (en) | 2002-06-15 | 2006-11-08 | Enteromed Inc | PREVENTION AND TREATMENT OF NON-ALCOHOLIC FAT TREATMENT DISEASE (NAFLD) BY ANTAGONISM OF THE RECEPTOR OF GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE (GIP) |
| FR2842209B1 (fr) | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
| WO2004022004A2 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| EP1605897B1 (en) | 2003-03-19 | 2012-07-25 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| CN1822851B (zh) | 2003-05-15 | 2011-04-13 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
| JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| EP1633390B1 (en) | 2003-06-03 | 2012-01-18 | Novo Nordisk A/S | Stabilized pharmaceutical glp-1 peptide compositions |
| KR100758755B1 (ko) | 2003-06-12 | 2007-09-14 | 일라이 릴리 앤드 캄파니 | Ｇｌｐ-1 유사체 융합 단백질 |
| US20050124550A1 (en) | 2003-06-18 | 2005-06-09 | Peri Krishna G. | Compounds that modulate the glucagon response and uses thereof |
| AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| WO2005035003A2 (en) | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| BRPI0417717A (pt) | 2003-12-18 | 2007-04-03 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| CA2573109A1 (en) | 2004-06-17 | 2006-01-26 | Thomas A. Dix | Non-natural amino acids |
| US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| EA011653B1 (ru) | 2005-02-11 | 2009-04-28 | Амилин Фармасьютикалз, Инк. | Аналоги и гибридные полипептиды gip с избираемыми свойствами |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| US20090062192A1 (en) | 2005-03-18 | 2009-03-05 | Novo Nordisk A/S | Dimeric Peptide Agonists of the Glp-1 Receptor |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| SI1881850T1 (sl) | 2005-05-13 | 2011-01-31 | Lilly Co Eli | Glp-1 pegilirane spojine |
| AU2006258841B2 (en) | 2005-06-13 | 2012-05-03 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| WO2007028633A2 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
| JP2009507847A (ja) | 2005-09-08 | 2009-02-26 | シャイア エルエルシー | 生体利用性を増強したｔ３及びｔ４のプロドラッグ |
| AU2006289259A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| EP1991575A1 (en) | 2006-02-21 | 2008-11-19 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
| EP2471811B1 (en) | 2006-02-22 | 2015-09-16 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
| ES2397659T3 (es) | 2006-03-15 | 2013-03-08 | Novo Nordisk A/S | Mezclas de amilina e insulina |
| US20090186817A1 (en) * | 2006-03-21 | 2009-07-23 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| JP2009534423A (ja) | 2006-04-20 | 2009-09-24 | アムジェン インコーポレイテッド | Ｇｌｐ−１化合物 |
| WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
| AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| WO2008023050A1 (en) | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| MX2009002523A (es) | 2006-09-08 | 2009-03-20 | Ambrx Inc | Polipeptido de plasma humano modificado o andamios fc y sus usos. |
| DE102006052755A1 (de) | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| EP2124974B1 (en) | 2007-01-05 | 2017-03-15 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| EP2487184A1 (en) * | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| CN103298935A (zh) | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| WO2009030774A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| EP2679597A1 (en) | 2007-09-05 | 2014-01-01 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009035540A2 (en) | 2007-09-07 | 2009-03-19 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| WO2009034117A1 (en) | 2007-09-11 | 2009-03-19 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
| WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| CN101918027A (zh) | 2007-11-02 | 2010-12-15 | 森托科尔奥索生物科技公司 | 半合成GLP-1肽-Fc融合构造、方法及其用途 |
| CA2703830A1 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| DK2596805T3 (da) | 2008-02-01 | 2021-12-13 | Ascendis Pharma As | Prodrug omfattende et lægemiddel-linker-konjugat |
| AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| BRPI0915282A2 (pt) | 2008-06-17 | 2017-02-07 | Univ Indiana Res & Tech Corp | agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| CN102245624B (zh) | 2008-12-19 | 2016-08-10 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| SG172291A1 (en) | 2008-12-19 | 2011-07-28 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
| MX2011006527A (es) | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Agentes medicinales unidos a dipeptido. |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| BRPI1014508A2 (pt) | 2009-06-16 | 2016-04-05 | Univ Indiana Res & Tech Corp | análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso" |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| JO2976B1 (en) | 2009-12-22 | 2016-03-15 | ايلي ليلي اند كومباني | Axentomodulin polypeptide |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| CN102834108A (zh) | 2010-01-27 | 2012-12-19 | 印第安纳大学研究及科技有限公司 | 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| CN103079587B (zh) | 2010-05-13 | 2016-05-11 | 印第安纳大学研究及科技有限公司 | 呈现核激素受体活性的胰高血糖素超家族肽 |
| CN103179976A (zh) | 2010-05-13 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 呈现g蛋白偶联受体活性的胰高血糖素超家族肽 |
| CN103179979A (zh) | 2010-06-24 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2009
- 2009-12-18 SG SG2011045283A patent/SG172291A1/en unknown
- 2009-12-18 EP EP16164599.9A patent/EP3075385A1/en not_active Withdrawn
- 2009-12-18 EP EP09833836A patent/EP2376097A4/en not_active Ceased
- 2009-12-18 US US13/130,962 patent/US8969288B2/en active Active
- 2009-12-18 CA CA2747499A patent/CA2747499A1/en not_active Abandoned
- 2009-12-18 KR KR1020117016193A patent/KR20110110174A/ko not_active Abandoned
- 2009-12-18 MX MX2011006524A patent/MX2011006524A/es active IP Right Grant
- 2009-12-18 AU AU2009327418A patent/AU2009327418A1/en not_active Abandoned
- 2009-12-18 AR ARP090104993A patent/AR074811A1/es not_active Application Discontinuation
- 2009-12-18 TW TW098143717A patent/TWI489992B/zh not_active IP Right Cessation
- 2009-12-18 CN CN2009801573173A patent/CN102325539A/zh active Pending
- 2009-12-18 RU RU2011129784/04A patent/RU2550696C2/ru not_active IP Right Cessation
- 2009-12-18 WO PCT/US2009/068745 patent/WO2010071807A1/en not_active Ceased
- 2009-12-18 PE PE2011001238A patent/PE20120332A1/es not_active Application Discontinuation
- 2009-12-18 BR BRPI0922969A patent/BRPI0922969A2/pt not_active IP Right Cessation
- 2009-12-18 JP JP2011542487A patent/JP2012512903A/ja active Pending
-
2011
- 2011-05-24 IL IL213113A patent/IL213113A/en not_active IP Right Cessation
- 2011-06-17 CL CL2011001498A patent/CL2011001498A1/es unknown
-
2015
- 2015-05-07 JP JP2015095017A patent/JP2015180649A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512903A5 (enExample) | ||
| RU2011129784A (ru) | Основанные на амидах пролекарства пептидов глюкагонового надсемейства | |
| KR102440323B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| JP7211712B2 (ja) | グルカゴン受容体アゴニスト | |
| RU2012153753A (ru) | Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов | |
| CN104945500B (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| RU2580317C2 (ru) | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов | |
| ES2351661T3 (es) | Péptido-2 análogo al glucagón. | |
| TWI554518B (zh) | 升糖素／ｇｌｐ－１受體共促效劑 | |
| US8551946B2 (en) | Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity | |
| RU2014117678A (ru) | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью | |
| JP2013518115A5 (enExample) | ||
| JP2013533849A5 (enExample) | ||
| US20160058881A1 (en) | Prodrugs with prolonged action | |
| RU2012153755A (ru) | Пептиды глюкагонового суперсемейства, обладающее активностью относительно ядерных гормональных рецепторов | |
| CA2877358A1 (en) | Glucagon analogs exhibiting gip receptor activity | |
| CA2877127A1 (en) | Analogs of glucagon exhibiting gip receptor activity | |
| CN103003300A (zh) | Glp-1受体激动剂和胃泌素的肽缀合物及其用途 | |
| JP2011524420A5 (enExample) | ||
| TW200938225A (en) | Ester-based peptide prodrugs | |
| CA2904332A1 (en) | Insulin-incretin conjugates | |
| JP2011502159A5 (enExample) | ||
| TW201130503A (en) | Glucagon/GLP-1 receptor co-agonists | |
| WO2024213022A1 (zh) | 肠促胰素类似物及其制备方法和应用 | |
| TW201143790A (en) | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |